PEOPLE - QLT makes appointment:
This article was originally published in Clinica
Biopharmaceutical company QLT (Vancouver, Canada) has appointed of Robert Butchofsky as president and CEO, effective immediately. My Butchofsky has been acting CEO since September 2005, before which he was working on the launch of QLT's flagship drug, Visudyne. The company has also just appointed Boyd Clarke as its new chairman.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.